Drug intelligence / Profile preview

Technetium Tc-99m P2045

Development stage: Preclinical
Lead developer: Andarix Pharmaceuticals
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides

Overview

Technetium Tc-99m P2045 is a radiopharmaceutical diagnostic agent developed by Andarix Pharmaceuticals and originated by Bayer HealthCare Pharmaceuticals. It is a peptide-based new molecular entity designed as a diagnostic imaging enhancer. This agent utilizes the radioactive isotope Technetium-99m, which emits gamma rays detectable by medical equipment, to target specific tissues or organs for diagnostic imaging purposes. It is intended as a companion diagnostic to help identify suitable patients.

Brand names: technetium Tc 99m + P2045
Other names: technetium Tc-99m-P2045technetium-99m-P2045technetium99m-P2045technetium 99m-P2045

Targets

SSTR (Somatostatin receptors)

Beyond the preview

Go deeper on Technetium Tc-99m P2045.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Technetium Tc-99m P2045.

Explore the full profile